Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Fluoroquinolone antibiotic

Ciprofloxacin

Dosage form
Tablet
Available strengths
250 mg, 500 mg, 750 mg
Drug class
Fluoroquinolone antibiotic
Common brand
Generic products

Clinical overview. Structured pharmacy reference for ciprofloxacin, an oral fluoroquinolone antibiotic reserved for susceptible bacterial infections when other treatment options are unsuitable, given its class-associated risks to tendons, nerves, and the central nervous system.

Indication

Common therapeutic uses

  • Treats susceptible bacterial infections of the respiratory tract, urinary tract, skin and soft tissue, and bone and joints, as well as infectious diarrhea, chronic bacterial prostatitis, typhoid fever, and uncomplicated gonorrhea.
  • Also used to eliminate meningococcal carriage in asymptomatic nasopharyngeal carriers, though it is not indicated for meningococcal meningitis itself.
  • Because of serious class-related risks, use is generally limited to situations where no other treatment options are suitable, such as uncomplicated cystitis with limited alternatives.

Pregnancy

Risk assessment and monitoring considerations

  • Should not be used in pregnancy unless the likely benefits outweigh the possible risk to the fetus; safety in human pregnancy has not been established, although animal studies did not show embryotoxic or teratogenic effects.

Breastfeeding

Infant exposure considerations

  • Safety in nursing women has not been established, and ciprofloxacin is excreted into breast milk; because of the potential for serious reactions in the infant, a decision should be made to discontinue either breastfeeding or the medication, weighing its importance to the mother.

Geriatrics

Dosing and tolerability considerations

  • Dosing should reflect illness severity and creatinine clearance because the drug is substantially eliminated by the kidney.
  • Patients usually over 60 years of age face a further increased risk of fluoroquinolone-associated tendon rupture and may also be more susceptible to QT-interval effects.

Pediatrics

Use in children and adolescents

  • Not recommended for patients under 18 years of age; safety and efficacy have not been established, and fluoroquinolones have caused joint and cartilage damage in juvenile animal studies.

Dosage & Administration

Practical dosing and administration

  • Dosing depends on the site and severity of infection, commonly 250 to 750 mg every 12 hours, or a single higher dose for uncomplicated gonorrhea, with treatment duration ranging from about 3 days to several weeks depending on the infection; complete the full prescribed course.
  • May be taken with or without food and with plenty of fluids, but separate dosing from dairy products, calcium-fortified foods, mineral supplements, or antacids by at least 2 hours before or 6 hours after; dose reduction is needed in significant renal impairment.

Common side effects

Frequently reported tolerability concerns

  • Ciprofloxacin may cause nausea.
  • Diarrhea may occur.
  • Abdominal pain or discomfort may occur.
  • Headache may occur.
  • Dizziness may occur.
  • Vomiting may occur.
  • Indigestion (dyspepsia) may occur.
  • Restlessness or trouble sleeping may occur.
  • Skin rash may occur.
  • Increased sweating may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Tendinitis and tendon rupture, most often involving the Achilles tendon, can occur, sometimes within 48 hours of starting treatment or even months after stopping.
  • Peripheral neuropathy (nerve pain, numbness, tingling, or weakness) can occur and may be permanent.
  • Central nervous system and psychiatric effects, including seizures, confusion, hallucinations, toxic psychosis, severe anxiety, depression, or suicidal thoughts, can occur, sometimes after the very first dose.
  • QT-interval prolongation with a risk of serious arrhythmia, including torsade de pointes, can occur.
  • Aortic aneurysm and aortic dissection risk may be increased, particularly in older adults or those with other risk factors.
  • Serious hypersensitivity reactions, including anaphylaxis, can occur, sometimes within 30 minutes of the first dose.
  • Severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis can occur.
  • Hepatic necrosis and life-threatening liver failure have been reported.
  • Clostridioides difficile-associated diarrhea and colitis can occur.
  • Severe blood glucose disturbances, including hypoglycemia resulting in coma or death, have been reported, particularly in diabetic patients on other glucose-lowering therapy.
  • Exacerbation of myasthenia gravis, including life-threatening muscle weakness, can occur.
  • Blood disorders such as hemolytic anemia, agranulocytosis, or life-threatening pancytopenia can occur.
  • Serious kidney problems such as interstitial nephritis or acute kidney failure can occur.
  • Seek immediate medical attention for tendon pain or swelling, sudden numbness or weakness, severe confusion or hallucinations, an irregular heartbeat or fainting, sudden severe abdominal, chest, or back pain, or signs of an allergic reaction such as facial swelling, rash, or difficulty breathing.

Use with caution

Situations requiring closer assessment

  • Use cautiously in patients with a known or suspected central nervous system disorder or seizure risk, renal impairment requiring dose reduction, diabetes treated with insulin or oral hypoglycemic agents, or cardiac conduction abnormalities and other QT-prolongation risk factors.
  • Avoid direct sunlight or ultraviolet light exposure because of photosensitivity risk, and use with added caution in patients over 60, those on corticosteroids, or organ transplant recipients because of higher tendon rupture risk.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to ciprofloxacin, other quinolone antibacterial agents, or any ingredient in the formulation.
  • Contraindicated with concurrent use of tizanidine, due to a marked, potentially dangerous increase in tizanidine blood levels.
  • Contraindicated with concurrent use of agomelatine (not currently marketed in Canada), due to a large increase in agomelatine exposure and hepatotoxicity risk.
  • Should not be used in patients with a history of tendon disease or disorder related to previous fluoroquinolone treatment.
  • Should be avoided in patients with a known history of myasthenia gravis, since fluoroquinolones can cause severe, potentially life-threatening muscle weakness.

Drug interactions

Clinically relevant combinations

  • Theophylline: combined use has caused serious and sometimes fatal reactions including cardiac arrest, seizures, and respiratory failure; theophylline levels should be monitored closely if coadministration cannot be avoided.
  • Caffeine and other xanthine derivatives, including pentoxifylline, can reach higher blood levels with ciprofloxacin; excessive caffeine intake should be avoided.
  • Clozapine, duloxetine, ropinirole, and lidocaine can reach higher blood levels with ciprofloxacin, since it inhibits the CYP1A2 enzyme that metabolizes them, increasing toxicity risk.
  • Class IA or III antiarrhythmics such as quinidine, procainamide, amiodarone, or sotalol can have an additive effect on QT-interval prolongation when combined with ciprofloxacin.
  • Antidiabetic agents such as glyburide or insulin: ciprofloxacin can disturb blood glucose control, so glucose should be monitored closely.
  • Oral anticoagulants such as warfarin: ciprofloxacin can increase the anticoagulant effect, so INR should be monitored frequently.
  • Phenytoin levels can be altered, either increased or decreased, with concurrent ciprofloxacin, so monitoring is recommended.
  • Cyclosporine: ciprofloxacin can transiently raise serum creatinine, requiring closer monitoring.
  • Methotrexate: ciprofloxacin can reduce its renal clearance, raising methotrexate levels and increasing toxicity risk.
  • Probenecid can raise and prolong ciprofloxacin blood levels by reducing its renal clearance.
  • Sildenafil blood levels can roughly double with concurrent ciprofloxacin use.
  • Ferrous sulfate, dairy products or calcium-fortified foods, antacids, sucralfate, and other multivalent cation or mineral products containing calcium, iron, or zinc can substantially reduce ciprofloxacin absorption if taken too close together.
  • NSAIDs may increase the risk of CNS stimulation and seizures when combined with fluoroquinolones.
  • Metoclopramide can speed up ciprofloxacin absorption, though it does not change overall bioavailability.

Food interactions

Meal-related administration

  • Can be taken with meals, but avoid taking it together with dairy products alone, calcium-fortified foods, or mineral-fortified drinks, since this can reduce absorption; separate ciprofloxacin from calcium-rich foods by at least 2 hours before or 6 hours after.

Time of administration

Practical scheduling

  • Take doses at evenly spaced intervals, commonly every 12 hours, with plenty of fluids; absorption is somewhat faster on an empty stomach.

Storage

Product handling

  • Store tablets at room temperature between 15 and 30 degrees C.

Patient take-away

Key counselling points for a quick closing summary

  • Ciprofloxacin is a fluoroquinolone antibiotic reserved for bacterial infections, such as certain urinary tract, respiratory, skin, or bone and joint infections, when other treatment options aren't suitable.
  • Take it exactly as prescribed, spaced evenly through the day (commonly every 12 hours), and complete the entire course even if you start feeling better early.
  • Common side effects include nausea, diarrhea, headache, dizziness, and stomach discomfort.
  • Call your doctor's office right away if you develop tendon pain or swelling, numbness, tingling, or unusual muscle weakness, confusion or hallucinations, an irregular heartbeat or fainting, or signs of an allergic reaction, since ciprofloxacin carries a boxed warning for these serious reactions.
  • It can be taken with or without food, but avoid taking it at the same time as dairy products, calcium-fortified foods, antacids, or mineral supplements; separate these by at least 2 hours before or 6 hours after your dose, and drink plenty of fluids.
  • Store the tablets at room temperature and avoid prolonged direct sun or ultraviolet light exposure while on treatment.

References

Source material and product information

  1. Health Canada Product Monograph — Ciprofloxacin

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.